Banque Cantonale Vaudoise Novavax Inc Transaction History

Banque Cantonale Vaudoise

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$3.89 - $20.97 $9,725 - $52,425	2,500 Added 500.0%	3,000 $38,000
Q2 2022 Aug 02, 2022	SELL	$36.28 - $75.29 $403,832 - $838,052	-11,131 Reduced 95.7%	500 $26,000
Q1 2022 May 09, 2022	BUY	$69.73 - $142.9 $785,020 - $1.61 Million	11,258 Added 3018.23%	11,631 $857,000
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $497,872 - $806,489	-3,700 Reduced 90.84%	373 $54,000
Q3 2021 Oct 29, 2021	SELL	$177.8 - $270.58 $1.04 Million - $1.59 Million	-5,877 Reduced 59.07%	4,073 $844,000
Q2 2021 Aug 11, 2021	BUY	$121.0 - $257.67 $1.19 Million - $2.54 Million	9,850 Added 9850.0%	9,950 $2.11 Million
Q1 2021 May 11, 2021	BUY	$112.98 - $319.93 $11,298 - $31,993	100 New	100 $18,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $680M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Banque Cantonale Vaudoise, based on Form 13F filings with the SEC.

Stay updated on Banque Cantonale Vaudoise with notifications on news.